219 related articles for article (PubMed ID: 28055976)
1. CD133 in brain tumor: the prognostic factor.
Li B; McCrudden CM; Yuen HF; Xi X; Lyu P; Chan KW; Zhang SD; Kwok HF
Oncotarget; 2017 Feb; 8(7):11144-11159. PubMed ID: 28055976
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
3. In vitro neurosphere formation correlates with poor survival in glioma.
C Jayakrishnan P; H Venkat E; M Ramachandran G; K Kesavapisharady K; N Nair S; Bharathan B; Radhakrishnan N; Gopala S
IUBMB Life; 2019 Feb; 71(2):244-253. PubMed ID: 30393962
[TBL] [Abstract][Full Text] [Related]
4. DNA hypomethylation of CD133 promoter is associated with recurrent glioma.
Sun B; Wan Z; Shen J; Ni L; Chen J; Cui M; Ni H; Shi W; Shi J
Oncol Rep; 2016 Aug; 36(2):1062-8. PubMed ID: 27374817
[TBL] [Abstract][Full Text] [Related]
5. Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.
Kim TM; Ko YH; Ha SJ; Lee HH
BMC Cancer; 2019 Feb; 19(1):119. PubMed ID: 30717708
[TBL] [Abstract][Full Text] [Related]
6. High miR-196a and low miR-367 cooperatively correlate with unfavorable prognosis of high-grade glioma.
Guan Y; Chen L; Bao Y; Qiu B; Pang C; Cui R; Wang Y
Int J Clin Exp Pathol; 2015; 8(6):6576-88. PubMed ID: 26261539
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
8. Acylglycerol kinase functions as an oncogene and an unfavorable prognostic marker of human gliomas.
Liu N; Wang Z; Cheng Y; Zhang P; Wang X; Yang H; Liu H; Zhang Y; Tu Y
Hum Pathol; 2016 Dec; 58():105-112. PubMed ID: 27574811
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of miR-378 correlates with tumor invasiveness and poor prognosis of patients with glioma.
Li B; Wang Y; Li S; He H; Sun F; Wang C; Lu Y; Wang X; Tao B
Int J Clin Exp Pathol; 2015; 8(6):7016-21. PubMed ID: 26261592
[TBL] [Abstract][Full Text] [Related]
11. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
12. CD133 is a marker of bioenergetic stress in human glioma.
Griguer CE; Oliva CR; Gobin E; Marcorelles P; Benos DJ; Lancaster JR; Gillespie GY
PLoS One; 2008; 3(11):e3655. PubMed ID: 18985161
[TBL] [Abstract][Full Text] [Related]
13. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
Wu B; Sun C; Feng F; Ge M; Xia L
J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of miRNA-155 methylation in anaplastic glioma.
Schliesser MG; Claus R; Hielscher T; Grimm C; Weichenhan D; Blaes J; Wiestler B; Hau P; Schramm J; Sahm F; Weiß EK; Weiler M; Baer C; Schmidt-Graf F; Schackert G; Westphal M; Hertenstein A; Roth P; Galldiks N; Hartmann C; Pietsch T; Felsberg J; Reifenberger G; Sabel MC; Winkler F; von Deimling A; Meisner C; Vajkoczy P; Platten M; Weller M; Plass C; Wick W
Oncotarget; 2016 Dec; 7(50):82028-82045. PubMed ID: 27880937
[TBL] [Abstract][Full Text] [Related]
16. Ion channel gene expression predicts survival in glioma patients.
Wang R; Gurguis CI; Gu W; Ko EA; Lim I; Bang H; Zhou T; Ko JH
Sci Rep; 2015 Aug; 5():11593. PubMed ID: 26235283
[TBL] [Abstract][Full Text] [Related]
17. The clinicopathological significance of CD133 and Sox2 in astrocytic glioma.
Abdelrahman AE; Ibrahim HM; Elsebai EA; Ismail EI; Elmesallamy W
Cancer Biomark; 2018; 23(3):391-403. PubMed ID: 30248046
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of microRNA-504 is associated with poor prognosis in high-grade glioma.
Guan Y; Chen L; Bao Y; Pang C; Cui R; Li G; Liu J; Wang Y
Int J Clin Exp Pathol; 2015; 8(1):727-34. PubMed ID: 25755767
[TBL] [Abstract][Full Text] [Related]
19. An integrated transcriptomic and computational analysis for biomarker identification in human glioma.
Xing W; Zeng C
Tumour Biol; 2016 Jun; 37(6):7185-92. PubMed ID: 26663173
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
